Phase II study of a weekly 24-hour infusion with 5-fluorouracil and simultaneous sodium-folinic acid in the first-line treatment of metastatic colorectal cancer

被引:17
|
作者
Hartung, G
Hofheinz, RD
Wein, A
Riedel, C
Rost, A
Fritze, D
Kreuser, ED
Drees, M
Kühnel, J
Hehlmann, R
Queisser, W
机构
[1] Univ Klinikum Rostock, Hamatol Onkol Abt, Klin & Poliklin Innere Med, D-18057 Rostock, Germany
[2] Univ Heidelberg, Onkol Zentrum, Med Klin 3, Univ Klinikum Mannheim, Mannheim, Germany
[3] Univ Erlangen Nurnberg, Med Klin 1, D-8520 Erlangen, Germany
[4] Klinikum Darmstadt, Med Klin 5, Darmstadt, Germany
[5] Krankenhaus Barmherzigen Bruder, Med Klin, Regensburg, Germany
[6] Medac GMBH, Wedel, Germany
来源
ONKOLOGIE | 2001年 / 24卷 / 05期
关键词
colorectal cancer; phase II study; 5-fluorouracil; calcium-folinic acid; sodium-folinic acid; weekly 24-hour infusion;
D O I
10.1159/000055126
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Background. A weekly continuous 24-hour infusion therapy with 5-fluorouracil (5-FU) and calcium - folinic acid (CA-FA) was shown to be an effective first-line treatment in advanced metastatic colorectal cancer. Sodium - folinic acid (S-FA) is a new formulation which, in contrast to CA-FA allows the simultaneous Lv. administration in combination with 5-FU in one pump. Patients and Methods; From 1997 to 1998, 51 patients [median age 60 (range 24-77) years; 38 male, 13 female] with metastatic colorectal cancer were recruited in 5 centers to receive weekly 24-hour infusions of 5-FU (2,600 mg/m(2)) and S-FA (500 mg/m(2)) dissolved in one pump for 6 weeks as first-line treatment. The treatment cycle was repeated after a 2-week rest period. Results: 1,178 administrations (median 24, range 3-54) were performed during the study. Out of 51 patients (median follow-up 20.2 months), 2 (3.9%) achieved complete remission (CR), 17 (33.3%) partial remission (PR), and 21 (41.2%) no change (NC). Progressive disease (PD) was observed in 11/51 (21.6%) patients, including 6 patients who did not complete the first cycle. Median time to tumor progression (TTP) was 8.5 months (95% Cl: 5.8-11.3). 32/51 (62.7%) patients survived for more than 1 year, the median survival was reached at 16.5 months (95%Cl: 10.2-22.8). Among major toxicities, NCL-CTC grade III/IV diarrhea occurred in 13/51 25.4%), grade III hand-foot syndrome in 6/51 (11.7% patients. Grade III/IV stomatitis was observed in 4/51 (7.8%), cardiac toxicity occurred in 2/51 patients (3.9%). Conclusion: Similar to conventional 24-hour 5-FU + CA-FA treatment, the combination with S-FA induced 37.2% objective responses with moderate toxicity. However, TTP seems favorable and the administration of S-FA is convenient, while saving costs and time for the patient in outpatient units.
引用
收藏
页码:457 / 462
页数:8
相关论文
共 50 条
  • [1] Phase-II-study of a 24-h infusion with 5-fluorouracil (5-FU) and simultaneous sodium-folinic acid in the first-line-treatment of advanced colorectal cancer: Interim analysis
    Hofheinz, R
    Hartung, G
    Wein, A
    Riedel, C
    Kuhfahl, J
    Rost, A
    Brecht, A
    Bolte, R
    Fritze, D
    Keilholz, U
    Kreuser, ED
    Queisser, W
    EUROPEAN JOURNAL OF CANCER, 1999, 35 : S81 - S81
  • [2] Paclitaxel and weekly 24-hour infusion of 5-fluorouracil folinic acid in advanced gastric cancer
    Bokemeyer, C
    Hartmann, JT
    Lampe, CS
    Clemens, MR
    Quietzsch, D
    Forkmann, L
    Kanz, L
    SEMINARS IN ONCOLOGY, 1997, 24 (06) : S96 - S100
  • [3] Second-line treatment of advanced colorectal cancer with a weekly simultaneous 24-hour infusion of 5-fluorouracil and sodium-folinate: A multicentre phase II trial
    Kuhfahl, J
    Steinbrecher, C
    Wagner, T
    Wagner, H
    Fritze, D
    Link, H
    Schulte, F
    Pichlmeier, U
    Kreuser, ED
    ONKOLOGIE, 2004, 27 (05): : 449 - 454
  • [4] Impact of surgery on survival in palliative patients with metastatic colorectal cancer after first line treatment with weekly 24-hour infusion of high-dose 5-fluorouracil and folinic acid
    Wein, A
    Riedel, C
    Köckerling, F
    Martus, P
    Baum, U
    Brueckl, WM
    Reck, T
    Ott, R
    Hänsler, J
    Bernatik, T
    Becker, D
    Schneider, T
    Hohenberger, W
    Hahn, EG
    ANNALS OF ONCOLOGY, 2001, 12 (12) : 1721 - 1727
  • [5] Comparison of a 48-hour infusion of 5-fluorouracil without folinic acid with 24-hour folinic acid/5-fluorouracil in patients with metastatic colorectal cancer refractory to bolus folinic acid/5-fluorouracil - A prospective cohort study
    Moehler, M
    Gutzler, F
    Steinmann, S
    Boehme, M
    Raeth, U
    Stremmel, W
    Galle, PR
    Rudi, J
    CHEMOTHERAPY, 2003, 49 (1-2) : 85 - 89
  • [6] Topotecan or a weekly 24-hour infusion in patients with advanced colorectal cancer pretreated with 5-fluorouracil/folinic acid.
    Quietzsch, D
    Baronius, W
    Jungberg, P
    Liebert, A
    TUMORDIAGNOSTIK & THERAPIE, 2000, 21 (03) : 68 - 75
  • [7] A phase II study of paclitaxel, weekly, 24-hour continuous infusion 5-fluorouracil, folinic acid and cisplatin in patients with advanced gastric cancer
    Kollmannsberger, C.
    Quietzsch, D.
    Haag, C.
    Lingenfelsers, T.
    Schroeder, M.
    Hartmann, J. T.
    Baronius, W.
    Hempel, V.
    Clemens, M.
    Kanz, L.
    Bokemeyer, C.
    BRITISH JOURNAL OF CANCER, 2000, 83 (04) : 458 - 462
  • [8] A phase II study of paclitaxel, weekly, 24-hour continuous infusion 5-fluorouracil, folinic acid and cisplatin in patients with advanced gastric cancer
    C Kollmannsberger
    D Quietzsch
    C Haag
    T Lingenfelser
    M Schroeder
    J T Hartmann
    W Baronius
    V Hempel
    M Clemens
    L Kanz
    C Bokemeyer
    British Journal of Cancer, 2000, 83 : 458 - 462
  • [9] Weekly high-dose 5-fluorouracil 24-hour infusion and intermediate-dose folinic acid bolus in metastatic colorectal cancer
    Stoffregen, C
    Zurborn, KH
    Boehme, V
    Schmid, A
    Lorenz, G
    Arendt, T
    Folsch, UR
    ONKOLOGIE, 1996, 19 (05): : 410 - 414